{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-275862","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.572571+00:00","generated_at":"2026-05-16T21:26:04.376319+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vor Biopharma announces $100M public offering of 10M shares at $10 each to fund telitacicept development","bullets":["10,000,000 shares at $10.00 each; expected net proceeds ~$93.7M (or $107.8M if underwriters' option fully exercised).","Proceeds to advance telitacicept clinical development including Phase 3 trial for primary Sjögren's Disease, plus manufacturing/pre-commercialization.","Offering expected to close November 12, 2025; underwriters have 30-day option for up to 1,500,000 additional shares.","As of Sept 30, 2025, outstanding shares were 9,026,922; offering represents ~111% dilution if fully exercised.","Company believes current cash plus proceeds will fund operations into Q2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-275862","json":"https://secwatch.observer/filing/0001193125-25-275862.json","markdown":"https://secwatch.observer/filing/0001193125-25-275862.md","text":"https://secwatch.observer/filing/0001193125-25-275862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525275862/0001193125-25-275862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525275862/vor-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:26:04.376319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}